Recent FDA-approved drugs are getting off to slow starts in the marketplace because of Coronavirus related issues; this is not good for stock prices (for example, look what has happened to AIMT). So, from my perspective, submitting the Leronlimab BLA at the end of March happens to be perfect timing; by the time the worst of the Coronavirus situation has ended (ie by September) we will have received our FDA approval (and lots of great national press), thereby ensuring a fast start in sales right out of the gate.